Nuvama cuts Aurobindo Pharma target to Rs 1,485 but retains ‘Buy' on healthy EBITDA margin
By News Desk Published on May 28, 2025, 08:26 IST
Nuvama Institutional Equities has retained its Buy rating on Aurobindo Pharma (ARBP) but revised its target price down to ₹1,485 from ₹1,677, citing a mixed Q4 performance and a cautious FY26 outlook.
The brokerage said revenue and adjusted EBITDA beat expectations, but PAT (profit after tax) missed estimates. Nuvama noted that the adjusted EBITDA margin of 22.6% was better than anticipated, reflecting effective cost control and operational efficiency.
The management has guided for single-digit growth and flat margins in FY26, while FY27 is expected to benefit from new product launches and biosimilar contributions in Europe. This could support stronger performance in the medium term.
Despite the margin outperformance, Nuvama has reduced its PAT estimates for FY26E and FY27E by 5% and 4% respectively, factoring in lower earnings visibility and conservative growth assumptions.
The report also flagged a potential future trigger in the form of a government announcement on minimum input price for PLI (Production Linked Incentive) scheme products, which could support sector margins.
Disclaimer: The views and recommendations expressed above are those of the brokerage firm. Business Upturn does not endorse or offer any investment advice.
News desk at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
10 hours ago
- Business Upturn
Accenture guidance lift reinforces CLSA's bullish view on Indian IT; Infosys, Tech Mahindra, Persistent top picks
By News Desk Published on June 23, 2025, 08:31 IST CLSA has reiterated its positive outlook on Indian IT services, following Accenture's decision to raise its FY25 organic growth guidance to 3–4%, citing strong traction in Gen AI, cloud, and digital transformation services. The brokerage noted that Accenture's market share gains are being driven by the integration of Gen AI across its offerings, with cognitive solutions being actively developed for multiple global clients. This momentum, according to CLSA, has strengthened the booking pipeline and supports the upgraded guidance. CLSA also pointed out that BFSI growth remains resilient, a trend which mirrors the performance of Indian IT companies in the sector. Given these developments, the brokerage has reaffirmed its overweight (OW) stance on the Indian IT portfolio, excluding LTIMindtree. Among the top picks in the sector, CLSA has listed Infosys, Tech Mahindra, and Persistent Systems, viewing them as best positioned to benefit from the ongoing digital shift and AI-led enterprise transformation. Disclaimer: The views expressed in this article are those of the brokerage firm and do not represent the views of this publication. Investors are advised to consult certified financial advisors before making any investment decisions. Ahmedabad Plane Crash News desk at
Business Upturn
10 hours ago
- Business Upturn
Polycab share: Jefferies maintains buy with Rs 7,150 target, estimates 26% EPS CAGR through FY28
By News Desk Published on June 23, 2025, 08:36 IST Jefferies has reiterated its buy rating on Polycab India Ltd, assigning a target price of ₹7,150 per share, as it highlighted robust growth across core and new business segments and strong future earnings visibility. Polycab shares have surged 25% since March 2025, currently trading at 34x FY26 earnings, only marginally above its 5-year average valuation, Jefferies noted. The brokerage emphasized that the company gained 1% market share in its core Cables & Wires (C&W) segment during FY25. Jefferies pointed to a ₹2,800 crore capital expenditure over the past four years, which significantly contributed to a 26% sales CAGR in the C&W segment. Additionally, the FMEG (Fast Moving Electrical Goods) segment turned profitable after 10 consecutive loss-making quarters, marking a major turnaround. The company's FY25 annual report also underscored Project 'Spring' and aggressive FY30 growth targets. Jefferies estimates a 26% CAGR in earnings per share (EPS) from FY25 to FY28, driven by a strong order book and improving margins in the FMEG segment. Disclaimer: The views and recommendations above are those of the respective brokerage firm. They do not represent the views of this publication. Investors are advised to consult their financial advisers before making any investment decisions. Ahmedabad Plane Crash News desk at
Business Upturn
10 hours ago
- Business Upturn
Accenture's Q3 slowdown offers limited cues for Indian IT: HSBC
By News Desk Published on June 23, 2025, 08:30 IST HSBC has stated that Accenture's Q3FY25 performance signals a slowdown compared to the first half of the fiscal year, but the implications for Indian IT services companies remain limited. Accenture has tightened its FY25 revenue growth guidance to 6–7%, indicating a more cautious outlook amid global macroeconomic headwinds. The company also reported a 7% year-on-year decline in deal wins in constant currency terms, suggesting softening client demand and delayed decision-making. Notably, the brokerage pointed out a sharper drop in outsourcing bookings, a segment that usually aligns more closely with traditional Indian IT services offerings. This could be seen as a potential risk for companies heavily reliant on outsourcing revenues. Despite the moderation, HSBC emphasized that these results do not offer a strong read-through for Indian IT companies, given the structural and geographic differences between Accenture's portfolio and that of its Indian peers. The cautious outlook adds to the mixed global signals being assessed by investors ahead of the upcoming earnings season in the Indian IT sector. Disclaimer: The views expressed in this article are based on brokerage reports and do not represent the views of this publication. Investors are advised to consult certified financial advisors before making any investment decisions. Ahmedabad Plane Crash News desk at
